TTOO T2 Biosystems, Inc. gains 37% Sep 15, 2017

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications, as well as T2HemoStat panel, which includes a range of hemostasis measurements, including platelet function, clotting time, and clot degradation. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease, a tick-borne illness. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts. http://www.priceseries.com/trade/TTOO-T2-Biosystems-Inc-stock-gains-37-percent-a-Trade-Record-by-priceSeries-2017080920170915.html